You are here:

Latest News
 

  • New App Uses ALS Patients with Speech Disabilities’ Own Voices to Help Them Communicate

    New App Uses ALS Patients with Speech Disabilities’ Own Voices to Help Them Communicate

    The first app for amyotrophic lateral sclerosis (ALS) patients who have begun to lose their speaking abilities was recently launched by UK company Therapy Box. The app was designed to substitute standard text-to-speech synthesis with a synthesizer based on the patient’s own voice. The Predictable 4 app has entered the ModelTalker program, at a cost of $140 annually, as a way of helping patients […]

  • Recent Genetics Research May Hold Clues to New ALS Treatments

    Recent Genetics Research May Hold Clues to New ALS Treatments

    Dr. Nancy Bonini A recent editorial published in the journal Neurology highlights the existing scope of clinical knowledge concerning genetic susceptibility that makes individuals prone to developing amyotrophic lateral sclerosis (ALS). The editorial content was based on a thorough review of the current literature conducted by ALS researchers and authors Dr. Nancy Bonini PhD, Florence […]

  • New Experimental Model Uses Astrocytes to Test Therapies for ALS

    New Experimental Model Uses Astrocytes to Test Therapies for ALS

    A research team from the University of Wisconsin-Madison Waisman Center led by Su Chun Zhang, established a simple model in mice to investigate the role of human astrocytes in neurologic diseases such as Amyotrophic Lateral Sclerosis (ALS), Rett Syndrome and Huntington’s disease. The study entitled “Human-derived neural progenitors functionally replace astrocytes in adult mice” appears in the […]

  • Neuralstem Introduces Novel Therapies for ALS at BIO CEO & Investor Conference

    Neuralstem Introduces Novel Therapies for ALS at BIO CEO & Investor Conference

    Dual platform regenerative medicine company, Neuralstem, Inc., is wrapping up its participation in the 17th Annual BIO CEO & Investor Conference taking place February 9 to the 10th at the Waldorf Astoria in New York. President and CEO, Richard Garr, was invited to present on the company’s proprietary therapeutic technology indicated for the treatment of diseases that affect the central nervous system, […]

  • ALS Tissue-Engineered Skin May Hold Key to Early Diagnoses

    ALS Tissue-Engineered Skin May Hold Key to Early Diagnoses

    A recent study, titled, “Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients,” published in the journal, Acta Neuropathologica Communications, details the creation of a novel tissue-engineered skin model for amyotrophic lateral sclerosis (ALS). ALS is a progressive neurodegenerative disease that specifically affects the motor nerve cells in the brain and […]

  • ALS Ice Bucket Challenge Funds its First Research Project in Canada

    ALS Ice Bucket Challenge Funds its First Research Project in Canada

    The ALS Society of Canada is proud to announce the first research project on amyotrophic lateral sclerosis (ALS) to receive funding raised from the viral ALS Ice Bucket Challenge. The Society also thanks the generous support of national non-profit organization, Brain Canada, and the Canadian Government. The Arthur J. Hudson Translational Team Grant will be used to study the clinical response of ALS patients to a […]

  • ALS Study Reveals a Domain Crucial for Degradation of Misfolded Proteins

    ALS Study Reveals a Domain Crucial for Degradation of Misfolded Proteins

    A recent study published in the journal Molecular Cell, revealed that a specific domain in a particular heat-shock protein plays a major role in the degradation of misfolded proteins. The study is entitled “The Hsp104 N-Terminal Domain Enables Disaggregase Plasticity and Potentiation”. Disorders such as Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) are […]

  • ALS Gene Variant May Be Accelerating Disease in One-Third of Patients

    ALS Gene Variant May Be Accelerating Disease in One-Third of Patients

    A team of researchers from the Penn State College of Medicine found that a specific gene variant found in a third of patients with Amyotrophic lateral sclerosis (ALS) is associated with faster disease progression. The results were found in mice models of ALS carrying only this gene variant, compared to mice that had the standard […]

  • Regulation of Enzyme HDAC6 May Be Relevant in ALS Treatment

    Regulation of Enzyme HDAC6 May Be Relevant in ALS Treatment

    A new study entitled “HDAC6 Is a Bruchpilot Deacetylase that Facilitates Neurotransmitter Release” was published in Cell Reports by Katarzyna Miskiewicz and Liya E. Jose, co-first authors of the study and part of Dr. Patrik Verstreken’s group from the VIB Center for the Biology of Disease and Center for Human Genetics and Leuven Research Institute […]

  • Inhibition of Neural Pumps May Hold Key to ALS Treatment Efficacy

    Inhibition of Neural Pumps May Hold Key to ALS Treatment Efficacy

    Last November, Dr. Piera Pasinelli, Ph.D., associate professor of neuroscience and Co-Director of the Weinberg Unit for ALS Research at Thomas Jefferson University, and her research team made an important discovery in the field of amyotrophic lateral sclerosis (ALS) research that may change the way the therapeutic protocols currently used to treat this debilitating disease […]

Back to Top